The functional basis for the observed associations of loss of RBM3 expression with tumour progression and poor prognosis in human cancer remains largely unclear, but in epithelial ovarian cancer (EOC), the association of RBM3 expression and improved outcome has to some extent been corroborated by in vitro data demonstrating an association between RBM3 expression and improved response to cisplatin treatment [11]. The gene discussed is RBM3; the disease is ovarian carcinoma.